Literature DB >> 29916856

Cardiovascular Side Effects of Tyrosine Kinase Inhibitor Ibrutinib (Imbruvica) and Interaction With Direct Oral Anticoagulant.

Muhammad Khalid1, Furqan Khattak2, Vijay Ramu2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29916856     DOI： 10.1097/MJT.0000000000000775

Source DB:  PubMed          Journal:  Am J Ther        ISSN： 1075-2765            Impact factor:   2.688


× No keyword cloud information.
  4 in total

1.  Left Atrial Appendage Occlusion as an Alternative to Anticoagulants in Ibrutinib-Induced Hemorrhagic Pericardial Effusion.

Authors:  Hafiz Jeelani; Muhammad Mubbashir Sheikh; Nayha Tahir; Grace Ying; Sonika Prasad; Maryana Yaremko; Jashan Gill
Journal:  JACC Case Rep       Date:  2022-06-15

2.  Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.

Authors:  Yanhua Zhou; Hongtao Lu; Meifeng Yang; Chenhong Xu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

3.  Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports.

Authors:  Silvia Fernandez; Camille Lenoir; Caroline Samer; Victoria Rollason
Journal:  Pharmacol Res Perspect       Date:  2020-10

Review 4.  The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia.

Authors:  Milo Gatti; Emanuel Raschi; Elisabetta Poluzzi; Cristian Martignani; Stefania Salvagni; Andrea Ardizzoni; Igor Diemberger
Journal:  Curr Heart Fail Rep       Date:  2020-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.